NCT06090422View on ClinicalTrials.gov

Ketamine for Combined Depression and Alcohol Use Disorder

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
DepressionAlcohol Use Disorder
Interventions
DRUG

Ketamine Hydrochloride

Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

DRUG

Midazolam Hydrochloride

Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

All Listed Sponsors
collaborator

University of Exeter

OTHER

lead

University Hospital of North Norway

OTHER

NCT06090422 - Ketamine for Combined Depression and Alcohol Use Disorder | Biotech Hunter | Biotech Hunter